查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1833578

2032年口服抗生素市场预测：按药物类别、活性频谱、适应症、病患小组、通路、剂型和地区进行的全球分析

Oral Antibiotics Market Forecasts to 2032 - Global Analysis By Drug Class, Spectrum of Activity, Indication, Patient Group, Distribution Channel, Formulation Type and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3个工作天内

价格

根据 Stratistics MRC 的数据，全球口服抗生素市场预计在 2025 年达到 514 亿美元，到 2032 年将达到 830.9 亿美元，预测期内的复合年增长率为 7.1%。

口服抗生素是口服药物，用于治疗体内细菌感染。抗生素的作用机转是消灭细菌或抑制其生长，增强免疫系统并控制疾病。口服抗生素有胶囊、锭剂或悬浮液等剂型，常用于治疗感染疾病、感染疾病、尿道感染及胃肠道感染疾病等疾病。使用口服抗生素时，正确的医疗指导至关重要，这样才能达到预期效果并最大限度地降低抗生素抗药性的风险。

据世界卫生组织 (WHO) 称，全球细菌性疾病负担日益加重，对有效治疗方法的需求也日益增长。

患者便利且经济高效

口服抗生素因其给药方便、治疗成本低而日益受到偏好。与静脉注射不同，口服製剂无需住院，是门诊治疗的理想选择。这种便利性尤其有利于慢性感染疾病和长期治疗。药物输送系统的技术进步正在提高生物有效性和患者依从性。新兴趋势包括缓释性胶囊和儿科口味改良混悬液。随着医疗保健系统优先考虑具有成本效益的解决方案，口服抗生素在已开发市场和新兴市场都越来越受欢迎。

副作用和安全问题

胃肠不适、过敏反应和微生物组崩坏是患者和临床医生通用关注的问题。监管机构正在加强安全标准，强制进行大规模临床试验和上市后监测。人工智慧与药物安全检测的整合有助于更有效地检测不利事件。小型製药公司往往难以应对合规成本和不断变化的安全通讯协定。这些挑战可能会延迟产品核准，并限制口服抗生素领域的创新。

新药开发

抗生素抗药性病原体的增加推动了对下一代口服抗生素的需求。製药公司正在投资研发具有标靶机制的新型化合物，以克服抗药性。基因组学和人工智慧驱动的药物研发正在加速开发平臺。生技新兴企业正在探索微生物友善製剂和窄频谱药物，以最大限度地减少附带损害。监管机构正在为突破性治疗方法提供快速核准和奖励。这种格局为製剂、给药和治疗标靶的创新创造了巨大的机会。

来自替代疗法的竞争

噬菌体疗法、免疫调节剂和益生菌等治疗方法在感染控制方面正日益受到临床关注。医院正在采用精准医疗方法，以减少对广谱抗生素的依赖。数位健康平台正在促进早期诊断和预防性护理，从而可能降低抗生素需求。供应链中断和原材料短缺进一步加剧了竞争压力。因此，口服抗生素市场正面临非抗生素疗法和先进生技药品日益激烈的竞争。

COVID-19的影响：

疫情显着改变了抗生素处方模式，导致门诊量减少，非紧急治疗延误。封锁措施扰乱了生产和全球供应链，导致关键口服药物短缺。然而，这场危机加速了数位医疗的普及，包括远距咨询和电子处方笺。监管机构已推出紧急通讯协定，以确保持续获得​​基本抗生素。疫情后的策略如今强调分散生产和弹性分销网络。对抗菌药物管理的重新关注正在重塑口服抗生素的未来使用。

预计频谱部分将成为预测期内最大的部分

由于频谱抗生素在各种感染疾病中的广泛适用性，预计在预测期内将占据最大的市场份额。在病原体尚未确定的情况下，这些药物是经验性治疗的首选。技术进步使得广谱频谱靶向性更强，从而降低了抗药性风险。医院和诊所正在大量使用这些药物来治疗急性和慢性感染疾病。联合治疗和双促效剂的创新正在增强其临床效用。除了改良的诊断工具外，频谱抗生素仍然是第一线治疗通讯协定的核心。

预计预测期内，悬吊部分将实现最高的复合年增长率

由于悬浮液适用于儿童和老年族群，预计在预测期内将达到最高成长率。这些製剂透过灵活的剂量和更佳的偏好提高了患者的依从性。遮罩味和稳定性技术的进步正在扩大其治疗范围。製造商正在开发即用型悬浮液製剂，以简化药房运作。门诊和家庭护理的兴起推动了对液体抗生素的需求。随着个人化医疗的发展，悬浮液正成为客製化给药策略中不可或缺的一部分。

比最大的地区

在预测期内，受医疗基础设施扩张和感染率上升的推动，亚太地区预计将占据最大的市场份额。印度、中国和日本等国家正在投资国内药品生产和抗生素管理计画。政府正在倡议该地区的可负担医疗服务和技术创新。该地区正在迅速普及数位健康平台和人工智慧辅助诊断技术。跨国公司与本地製造商之间的策略联盟正在加强市场渗透。在中阶不断壮大和医疗保健意识不断提升的推动下，亚太地区将继续成为重要的成长引擎。

复合年增长率最高的地区：

预计北美地区在预测期内的复合年增长率最高。美国和加拿大在口服给药和抗药性监测方面处于领先地位。监管机构正在简化新型抗生素和配方改良的核准途径。医院正在整合电子处方和基于人工智慧的感染追踪技术，以优化抗生素的使用。该地区受益于强大的报销框架和门诊治疗的高采用率。随着抗菌素抗药性成为公共卫生优先事项，北美正在引领全球抗生素创新的步伐。

免费客製化服务：

此报告的订阅者可以选择以下免费自订选项之一：

  • 公司简介
    • 对最多三家其他市场公司进行全面分析
    • 主要企业的SWOT分析（最多3家公司）
  • 区域细分
    • 根据客户兴趣对主要国家进行的市场估计、预测和复合年增长率（註：基于可行性检查）
  • 竞争基准化分析
    • 根据产品系列、地理分布和策略联盟对主要企业基准化分析

目录

第一章执行摘要

第二章 前言

  • 概述
  • 相关利益者
  • 调查范围
  • 调查方法
    • 资料探勘
    • 数据分析
    • 数据检验
    • 研究途径
  • 研究材料
    • 主要研究资料
    • 次级研究资讯来源
    • 先决条件

第三章市场走势分析

  • 驱动程式
  • 抑制因素
  • 机会
  • 威胁
  • 新兴市场
  • COVID-19的影响

第四章 波特五力分析

  • 供应商的议价能力
  • 买方的议价能力
  • 替代品的威胁
  • 新进入者的威胁
  • 竞争对手之间的竞争

5. 全球口服抗生素市场（依药物类别）

  • 青霉素
  • Aminoglycosides
  • 头孢菌素类
  • 磺胺类药物
  • 大环内酯类
  • Fluoroquinolones
  • 四环霉素
  • 其他药物类别

6. 全球口服抗生素市场（依活性频谱）

  • 频谱抗生素
  • 窄效抗生素

7. 全球口服抗生素市场（按适应症）

  • 呼吸道感染疾病
  • 尿道感染
  • 牙齿感染疾病
  • 皮肤和软组织感染疾病
  • 性行为感染传染病
  • 胃肠道感染疾病
  • 其他适应症

8. 全球口服抗生素市场（依病患小组）

  • 成人
  • 老年人
  • 孩子们

9. 全球口服抗生素市场（依通路）

  • 医院药房
  • 网路药局
  • 零售药局

10. 全球口服抗生素市场（按剂型）

  • 药片
  • 粉末
  • 胶囊
  • 暂停

11. 全球口服抗生素市场（按地区）

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙
    • 其他欧洲国家
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 纽西兰
    • 韩国
    • 其他亚太地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 其他南美
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 卡达
    • 南非
    • 其他中东和非洲地区

第十二章 重大进展

  • 协议、伙伴关係、合作和合资企业
  • 收购与合併
  • 新产品发布
  • 业务扩展
  • 其他关键策略

第十三章：企业概况

  • Pfizer Inc.
  • Bristol Myers Squibb
  • Merck & Co., Inc.
  • Eli Lilly and Company
  • GlaxoSmithKline plc（GSK）
  • Astellas Pharma Inc.
  • Novartis AG
  • Cipla Ltd.
  • Sanofi
  • Roche Holding AG
  • Johnson & Johnson
  • Teva Pharmaceutical Industries Ltd.
  • Bayer AG
  • Takeda Pharmaceutical Company Limited
  • Abbott Laboratories
Product Code: SMRC31411

According to Stratistics MRC, the Global Oral Antibiotics Market is accounted for $51.40 billion in 2025 and is expected to reach $83.09 billion by 2032 growing at a CAGR of 7.1% during the forecast period. Oral antibiotics are drugs administered orally to treat bacterial infections in the body. They function by eliminating bacteria or hindering their multiplication, supporting the immune system in controlling illness. Offered as capsules, tablets, or liquid suspensions, they are frequently used for conditions like respiratory, skin, urinary tract, and digestive infections. Proper medical guidance is essential when using oral antibiotics to achieve desired outcomes and minimize the risk of antibiotic resistance.

According to the World Health Organization, the global burden of bacterial diseases continues to escalate, prompting a heightened demand for effective treatment options.

Market Dynamics:

Driver:

Patient convenience and cost-effectiveness

The growing preference for oral antibiotics stems from their ease of administration and reduced treatment costs. Unlike intravenous therapies, oral formulations eliminate the need for hospital visits, making them ideal for outpatient care. This convenience is especially beneficial for chronic infections and long-term therapies. Technological advancements in drug delivery systems are enhancing bioavailability and patient adherence. Emerging trends include extended-release capsules and taste-masked suspensions for pediatric use. As healthcare systems prioritize cost-effective solutions, oral antibiotics are gaining traction across both developed and emerging markets.

Restraint:

Adverse side effects and safety concerns

Gastrointestinal disturbances, allergic reactions, and microbiome disruption are common concerns among patients and clinicians. Regulatory agencies are tightening safety standards, requiring extensive clinical trials and post-marketing surveillance. The integration of AI in pharmacovigilance is helping detect adverse events more efficiently. Smaller pharmaceutical firms often struggle with compliance costs and evolving safety protocols. These challenges can delay product approvals and limit innovation in the oral antibiotics space.

Opportunity:

Novel drug development

The rise of antibiotic-resistant pathogens is fueling demand for next-generation oral antibiotics. Pharmaceutical companies are investing in novel compounds with targeted mechanisms to overcome resistance. Advances in genomics and AI-driven drug discovery are accelerating the development pipeline. Biotech startups are exploring microbiome-friendly formulations and narrow-spectrum agents to minimize collateral damage. Regulatory bodies are offering fast-track approvals and incentives for breakthrough therapies. This landscape presents significant opportunities for innovation in formulation, delivery, and therapeutic targeting.

Threat:

Competition from alternative therapies

Therapies such as phage therapy, immunomodulators, and probiotics are gaining clinical interest for infection management. Hospitals are adopting precision medicine approaches that reduce reliance on broad-spectrum antibiotics. Digital health platforms are promoting early diagnosis and preventive care, potentially lowering antibiotic demand. Supply chain disruptions and raw material shortages further intensify competitive pressures. Thus, the oral antibiotics market faces increasing competition from non-antibiotic treatments and advanced biologics.

Covid-19 Impact:

The pandemic significantly altered antibiotic prescribing patterns, with reduced outpatient visits and delayed non-urgent treatments. Lockdowns disrupted manufacturing and global supply chains, leading to shortages in key oral formulations. However, the crisis accelerated digital health adoption, including remote consultations and e-prescriptions. Regulatory agencies introduced emergency protocols to ensure continued access to essential antibiotics. Post-pandemic strategies now emphasize decentralized production and resilient distribution networks. The renewed focus on antimicrobial stewardship is reshaping the future of oral antibiotic usage.

The spectrum segment is expected to be the largest during the forecast period

The spectrum segment is expected to account for the largest market share during the forecast period, due to its broad applicability across various infections. These drugs are favored for empirical therapy when pathogen identification is pending. Technological advancements are enabling more precise spectrum targeting, reducing resistance risks. Hospitals and clinics rely heavily on these formulations for both acute and chronic infections. Innovations in combination therapies and dual-action agents are reinforcing their clinical utility. As diagnostic tools improve, spectrum antibiotics remain central to frontline treatment protocols.

The suspensions segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the suspensions segment is predicted to witness the highest growth rate, driven by their suitability for pediatric and geriatric populations. These formulations offer flexible dosing and improved palatability, enhancing patient compliance. Advances in taste-masking and stability technologies are expanding their therapeutic range. Manufacturers are developing ready-to-use suspensions to streamline pharmacy operations. The rise in outpatient care and home-based treatments is boosting demand for liquid antibiotics. As personalized medicine gains momentum, suspensions are becoming integral to tailored dosing strategies.

Region with largest share:

During the forecast period, the Asia Pacificregion is expected to hold the largest market share, supported by expanding healthcare infrastructure and rising infection rates. Countries like India, China, and Japan are investing in domestic pharmaceutical production and antibiotic stewardship programs. Government initiatives are promoting affordable access and local innovation. The region is witnessing rapid adoption of digital health platforms and AI-assisted diagnostics. Strategic collaborations between global firms and regional manufacturers are enhancing market penetration. With a growing middle class and increasing healthcare awareness, Asia Pacific remains a key growth engine.

Region with highest CAGR:

Over the forecast period, the North America region is anticipated to exhibit the highest CAGR, driven by robust R&D and advanced healthcare systems. The U.S. and Canada are pioneering innovations in oral drug delivery and resistance monitoring. Regulatory bodies are streamlining approval pathways for novel antibiotics and reformulations. Hospitals are integrating electronic prescribing and AI-based infection tracking to optimize antibiotic use. The region benefits from strong reimbursement frameworks and high adoption of outpatient therapies. As antimicrobial resistance becomes a public health priority, North America is setting the pace for global antibiotic innovation.

Key players in the market

Some of the key players in Oral Antibiotics Market include Pfizer Inc., Bristol Myers Squibb, Merck & Co., Inc., Eli Lilly and Company, GlaxoSmithKline plc (GSK), AstellasPharma Inc., Novartis AG, Cipla Ltd., Sanofi, Roche Holding AG, Johnson & Johnson, Teva Pharmaceutical Industries Ltd., Bayer AG, Takeda Pharmaceutical Company Limited, and Abbott Laboratories.

Key Developments:

In September2025, Pfizer Inc. and Metsera, Inc. announced the companies have entered into a definitive agreement under which Pfizer will acquire Metsera, a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and cardiometabolic diseases. The acquisition brings deep expertise and a portfolio of differentiated oral and injectable incretin, non-incretin and combination therapy candidates with potential best-in-class efficacy and safety profiles.

In July2025, The Bristol Myers Squibb-Pfizer Alliance announced a new direct-to-patient option for purchasing Eliquis(R) (apixaban) via our Alliance's patient resource Eliquis 360 Support. The offering provides an opportunity for uninsured, underinsured, or self-pay patients to significantly lower their out-of-pocket costs for this critical medicine. Eliquis is relied upon by millions of Americans daily and this program will provide a simple and transparent way to access it.

Drug Classes Covered:

  • Penicillins
  • Aminoglycosides
  • Cephalosporins
  • Sulfonamides
  • Macrolides
  • Fluoroquinolones
  • Tetracyclines
  • Other Drug Classes

Spectrum of Activities Covered:

  • Broad-Spectrum Antibiotics
  • Narrow-Spectrum Antibiotics

Indications Covered:

  • Respiratory Tract Infections
  • Urinary Tract Infections
  • Dental Infections
  • Skin and Soft Tissue Infections
  • Sexually Transmitted Infections
  • Gastrointestinal Infections
  • Other Indications

Patient Groups Covered:

  • Adults
  • Geriatrics
  • Pediatrics

Distribution Channels Covered:

  • Hospital Pharmacies
  • Online Pharmacies
  • Retail Pharmacies

Formulation Types Covered:

  • Tablets
  • Powders
  • Capsules
  • Suspensions

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Emerging Markets
  • 3.7 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Oral Antibiotics Market, By Drug Class

  • 5.1 Introduction
  • 5.2 Penicillins
  • 5.3 Aminoglycosides
  • 5.4 Cephalosporins
  • 5.5 Sulfonamides
  • 5.6 Macrolides
  • 5.7 Fluoroquinolones
  • 5.8 Tetracyclines
  • 5.9 Other Drug Classes

6 Global Oral Antibiotics Market, By Spectrum of Activity

  • 6.1 Introduction
  • 6.2 Broad-Spectrum Antibiotics
  • 6.3 Narrow-Spectrum Antibiotics

7 Global Oral Antibiotics Market, By Indication

  • 7.1 Introduction
  • 7.2 Respiratory Tract Infections
  • 7.3 Urinary Tract Infections
  • 7.4 Dental Infections
  • 7.5 Skin and Soft Tissue Infections
  • 7.6 Sexually Transmitted Infections
  • 7.7 Gastrointestinal Infections
  • 7.8 Other Indications

8 Global Oral Antibiotics Market, By Patient Group

  • 8.1 Introduction
  • 8.2 Adults
  • 8.3 Geriatrics
  • 8.4 Pediatrics

9 Global Oral Antibiotics Market, By Distribution Channel

  • 9.1 Introduction
  • 9.2 Hospital Pharmacies
  • 9.3 Online Pharmacies
  • 9.4 Retail Pharmacies

10 Global Oral Antibiotics Market, By Formulation Type

  • 10.1 Introduction
  • 10.2 Tablets
  • 10.3 Powders
  • 10.4 Capsules
  • 10.5 Suspensions

11 Global Oral Antibiotics Market, By Geography

  • 11.1 Introduction
  • 11.2 North America
    • 11.2.1 US
    • 11.2.2 Canada
    • 11.2.3 Mexico
  • 11.3 Europe
    • 11.3.1 Germany
    • 11.3.2 UK
    • 11.3.3 Italy
    • 11.3.4 France
    • 11.3.5 Spain
    • 11.3.6 Rest of Europe
  • 11.4 Asia Pacific
    • 11.4.1 Japan
    • 11.4.2 China
    • 11.4.3 India
    • 11.4.4 Australia
    • 11.4.5 New Zealand
    • 11.4.6 South Korea
    • 11.4.7 Rest of Asia Pacific
  • 11.5 South America
    • 11.5.1 Argentina
    • 11.5.2 Brazil
    • 11.5.3 Chile
    • 11.5.4 Rest of South America
  • 11.6 Middle East & Africa
    • 11.6.1 Saudi Arabia
    • 11.6.2 UAE
    • 11.6.3 Qatar
    • 11.6.4 South Africa
    • 11.6.5 Rest of Middle East & Africa

12 Key Developments

  • 12.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 12.2 Acquisitions & Mergers
  • 12.3 New Product Launch
  • 12.4 Expansions
  • 12.5 Other Key Strategies

13 Company Profiling

  • 13.1 Pfizer Inc.
  • 13.2 Bristol Myers Squibb
  • 13.3 Merck & Co., Inc.
  • 13.4 Eli Lilly and Company
  • 13.5 GlaxoSmithKline plc (GSK)
  • 13.6 Astellas Pharma Inc.
  • 13.7 Novartis AG
  • 13.8 Cipla Ltd.
  • 13.9 Sanofi
  • 13.10 Roche Holding AG
  • 13.11 Johnson & Johnson
  • 13.12 Teva Pharmaceutical Industries Ltd.
  • 13.13 Bayer AG
  • 13.14 Takeda Pharmaceutical Company Limited
  • 13.15 Abbott Laboratories

List of Tables

  • Table 1 Global Oral Antibiotics Market Outlook, By Region (2024-2032) ($MN)
  • Table 2 Global Oral Antibiotics Market Outlook, By Drug Class (2024-2032) ($MN)
  • Table 3 Global Oral Antibiotics Market Outlook, By Penicillins (2024-2032) ($MN)
  • Table 4 Global Oral Antibiotics Market Outlook, By Aminoglycosides (2024-2032) ($MN)
  • Table 5 Global Oral Antibiotics Market Outlook, By Cephalosporins (2024-2032) ($MN)
  • Table 6 Global Oral Antibiotics Market Outlook, By Sulfonamides (2024-2032) ($MN)
  • Table 7 Global Oral Antibiotics Market Outlook, By Macrolides (2024-2032) ($MN)
  • Table 8 Global Oral Antibiotics Market Outlook, By Fluoroquinolones (2024-2032) ($MN)
  • Table 9 Global Oral Antibiotics Market Outlook, By Tetracyclines (2024-2032) ($MN)
  • Table 10 Global Oral Antibiotics Market Outlook, By Other Drug Classes (2024-2032) ($MN)
  • Table 11 Global Oral Antibiotics Market Outlook, By Spectrum of Activity (2024-2032) ($MN)
  • Table 12 Global Oral Antibiotics Market Outlook, By Broad-Spectrum Antibiotics (2024-2032) ($MN)
  • Table 13 Global Oral Antibiotics Market Outlook, By Narrow-Spectrum Antibiotics (2024-2032) ($MN)
  • Table 14 Global Oral Antibiotics Market Outlook, By Indication (2024-2032) ($MN)
  • Table 15 Global Oral Antibiotics Market Outlook, By Respiratory Tract Infections (2024-2032) ($MN)
  • Table 16 Global Oral Antibiotics Market Outlook, By Urinary Tract Infections (2024-2032) ($MN)
  • Table 17 Global Oral Antibiotics Market Outlook, By Dental Infections (2024-2032) ($MN)
  • Table 18 Global Oral Antibiotics Market Outlook, By Skin and Soft Tissue Infections (2024-2032) ($MN)
  • Table 19 Global Oral Antibiotics Market Outlook, By Sexually Transmitted Infections (2024-2032) ($MN)
  • Table 20 Global Oral Antibiotics Market Outlook, By Gastrointestinal Infections (2024-2032) ($MN)
  • Table 21 Global Oral Antibiotics Market Outlook, By Other Indications (2024-2032) ($MN)
  • Table 22 Global Oral Antibiotics Market Outlook, By Patient Group (2024-2032) ($MN)
  • Table 23 Global Oral Antibiotics Market Outlook, By Adults (2024-2032) ($MN)
  • Table 24 Global Oral Antibiotics Market Outlook, By Geriatrics (2024-2032) ($MN)
  • Table 25 Global Oral Antibiotics Market Outlook, By Pediatrics (2024-2032) ($MN)
  • Table 26 Global Oral Antibiotics Market Outlook, By Distribution Channel (2024-2032) ($MN)
  • Table 27 Global Oral Antibiotics Market Outlook, By Hospital Pharmacies (2024-2032) ($MN)
  • Table 28 Global Oral Antibiotics Market Outlook, By Online Pharmacies (2024-2032) ($MN)
  • Table 29 Global Oral Antibiotics Market Outlook, By Retail Pharmacies (2024-2032) ($MN)
  • Table 30 Global Oral Antibiotics Market Outlook, By Formulation Type (2024-2032) ($MN)
  • Table 31 Global Oral Antibiotics Market Outlook, By Tablets (2024-2032) ($MN)
  • Table 32 Global Oral Antibiotics Market Outlook, By Powders (2024-2032) ($MN)
  • Table 33 Global Oral Antibiotics Market Outlook, By Capsules (2024-2032) ($MN)
  • Table 34 Global Oral Antibiotics Market Outlook, By Suspensions (2024-2032) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.